Results 141 to 150 of about 36,129 (239)

Pathogenesis of hidradenitis suppurativa: From susceptibility to chronicity

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
This review describes hidradenitis suppurativa as a heterogeneous disorder in which genetic susceptibility, epithelial dysfunction, environmental exposures, immune activation and microbial ecology converge differently across patients and disease stages.
Kelsey R. van Straalen   +5 more
wiley   +1 more source

Optimizing surgery in hidradenitis suppurativa

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Surgery in hidradenitis suppurativa should be matched to disease extent. A structured six‐step approach—comprehensive assessment, optimal timing, ultrasound‐guided mapping, tailored intervention, individualized reconstruction and structured wound care—integrated with targeted systemic therapy optimizes outcomes and reduces recurrence.
Eva Vilarrasa   +7 more
wiley   +1 more source

Hidradenitis suppurativa skin microbiome: In‐depth analysis and modulation by systemic therapies

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Hidradenitis suppurativa skin exhibits profound dysbiosis, characterized by the depletion of homeostatic commensals and expansion of anaerobic pathogens. Longitudinal evaluation reveals that while systemic antibiotics successfully reverse HS dysbiosis, biologics (adalimumab and secukinumab) fail to clear pathogens despite clinical healing.
Yacine Amar   +8 more
wiley   +1 more source

Adalimumab Reduces Epicardial Adipose Tissue in Psoriasis: A Post Hoc Analysis of a Randomized Placebo-Controlled Clinical Trial. [PDF]

open access: yesPsoriasis (Auckl)
Ramessur R   +7 more
europepmc   +1 more source

Risk of cancer in psoriasis patients treated with biologic therapy: A BADBIR cohort study

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
No evidence of an increased risk of incident cancer or KC was observed with biologic versus non‐biologic systemic therapies or across the biologic classes evaluated. Abstract Background There are concerns that biologic therapies for psoriasis may increase cancer risk. Objectives To compare risks of (i) incident cancer excluding keratinocyte carcinomas (
Oras A. Alabas   +9 more
wiley   +1 more source

Obesity‐associated transcriptomic remodelling in hidradenitis suppurativa and treatment response

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
This review highlights that adiposity systemically primes HS through adipokine dysregulation and insulin resistance, contributing to lesional metabolic reprogramming and perilesional barrier dysfunction. Current evidence indicates that obesity exacerbates disease severity and attenuates responses to biologic therapies, supporting the classification of ...
Sahil Kapur   +9 more
wiley   +1 more source

Efficacy and Safety of Risankizumab Among Patients With Ulcerative Colitis in East Asia: A Post Hoc Analysis of Two Randomized Clinical Trials

open access: yesJournal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Background and Aim Risankizumab, a monoclonal interleukin 23p19 antibody, is a treatment for ulcerative colitis. This post hoc analysis reports the efficacy and safety of risankizumab for ulcerative colitis in patients in East Asia from the global phase 3 clinical trials. Methods In the 12‐week, phase 2b/3 induction study (NCT03398148), adults
Ken Takeuchi   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy